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Abstract
Background There are scarce data in Scandinavia about treatment satisfaction among patients with psoriasis (PsO)
and/or psoriatic arthritis (PsA). The number of patients receiving systemic treatment is unknown.
Objective To describe patients’ experience of treatments for PsO/PsA in Sweden, Denmark and Norway, addressing
communication with physicians, satisfaction with treatment and concerns regarding treatment options.
Methods The NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP) asked 22 050 adults (randomly
selected from the YouGov panels in Sweden, Denmark and Norway) whether they had PsO/PsA. A total of 1264 individu-
als who reported physician-diagnosed PsO/PsA were invited to participate in the full survey; 96.6% responded positively.
Results Systemic treatment use was reported by 14.6% (biologic: 8.1%) of respondents with PsO only and by 58.5%
(biologic: 31.8%) of respondents with PsA. Biologic treatments were more frequently reported by respondents consider-
ing their disease severe (26.8% vs 6.7% non-severe) and those who were members of patient organizations (40.7% vs
6.9% non-members). Discussing systemic treatments with their physician was reported significantly more frequently by
respondents with PsA, those perceiving their disease as severe (although 35.2% had never discussed systemic treat-
ment with their physician) and those reporting being a member of a patient organization (P < 0.05). Many respondents
reported health risk concerns and dissatisfaction with their treatment. Of special interest was that respondents aged 45–
75 years reported less experience with biologics (8.1%) than those aged 18–44 years (21.5%). The older respondents
also reported more uncertainty regarding long-term health risks related to systemic treatments (most [66.7–72.9%]
responded ‘do not know’ when asked about the risk of systemic options).
Conclusion It appears likely that substantial numbers of Scandinavians suffering from severe PsO/PsA are not receiv-
ing optimal treatment from a patient perspective, particularly older patients. Also, one-third of respondents with severe
symptoms had never discussed systemic treatment with a physician.
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Introduction
Psoriasis (PsO) is a chronic inflammatory skin disease associated
with significant physical and psychosocial burden. The global
prevalence of PsO in adults is around 3%; however, estimates
from studies in Norway, Sweden and Denmark are consistent
with a relatively high prevalence in the Scandinavian region
(3.9–11.5%).1–5 Up to 35% of individuals with PsO will develop
psoriatic arthritis (PsA), which is associated with decreased
physical function, increased comorbidities and a substantial
reduction in quality of life.6–8 PsO and PsA disease management
requires lifelong treatment, which can itself impose additional
clinical and psychological burdens. Therapeutic approaches
include topical treatments and phototherapy for milder forms of
PsO on the skin and scalp and systemic treatments, which are
recommended for more severe manifestations.9–13 Traditional
oral systemic therapies such as methotrexate, acitretin and
cyclosporine have been available for many years, but their
effective use can be hindered by patient intolerance and organ-
specific toxicities.12,14 Several subcutaneously and intravenously
administered biologics targeting cytokines involved in the patho-
genesis of PsO and PsA have recently been approved.15 These
agents are usually recommended for use after failure of conven-
tional systemic therapy.9–13,16,17 Despite the availability of sev-
eral options for systemic treatment of PsO and PsA, and
published guidelines recommending their use in patients with
severe symptoms,11–13 some studies suggest that many patients
remain undertreated or unsatisfied with their treatment.18–21
The largest global probability survey to be conducted with
patients suffering from PsO and PsA, the Multinational Assess-
ment of PsO and PsA (MAPP), highlighted that although treat-
ment satisfaction was fairly high among those with non-severe
symptoms, many of those with severe disease were undertreated;
for example, >80% of patients with an affected body surface area
≥4 palms were receiving no treatment or topical therapy alone
and 60% of patients with PsA were not being treated for their
joint disease.20 Other studies have also shown low levels of
treatment satisfaction and a lack of systemic treatment use
among patients with severe psoriasis.18,22
The MAPP survey excluded Scandinavian countries; there-
fore, the NORPAPP was conducted to gain a better understand-
ing of the treatment of PsO and PsA in Sweden, Denmark and
Norway. The purpose of this study was to provide some insight
into the main challenges faced by people living with PsO and
PsA in these countries and to understand patients’ perspectives
on communication with the healthcare system and the different
treatments prescribed. In this report, we focus on respondent’s
perspectives on, and satisfaction with, the different available
treatments for PsO and PsA.
Materials and methods
YouGov (an international Internet-based market research firm)
conducted the survey during November and December 2015 in
Sweden, Denmark and Norway following the International
Chamber of Commerce (ICC)/European Society for Opinion
and Marketing Research (ESOMAR) International Code on
Market, Opinion and Social Research and Data Analytics, as pre-
viously described.2 The survey was conducted in accordance
with ethical standards required in each participating country. In
brief, 22 050 adults (aged 18–74 years) from the YouGov panels
were asked whether they had any type of PsO or PsA. Active
sampling was used to ensure that this initial survey population
was representative of the adult population in each country in
terms of age and gender. All 1264 individuals who reported
physician-diagnosed PsO or PsA were invited to participate in
the full survey, which was completed via an online link sent by
email, and the response rate was 96.6% (1221 respondents). The
questions explored in this paper addressed: patterns of treatment
use, whether or not systemic treatments (including biologics)
had been discussed with a physician, perceptions of the long-
term health risk of treatments, and satisfaction with systemic
treatments with a specific focus on methotrexate and biologics
(Appendix).
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Respondent data were weighted to match the demographics
(gender and age) of each country. Significant deviations in
responses between subgroups based on country, diagnoses, age,
perceived severity of their condition, patient organization mem-
bership and frequency of physician contact were assessed using
chi-squared tests and z-tests with Bonferroni corrections (total
a = 0.05) for comparisons of multiple answers within each ques-
tion. Since the NORPAPP was designed to investigate patients’
perspectives, a subjective measure was used to define subgroups
based on severity. Respondents were asked how they would rate
the severity of their condition over the past 12 months and were
then grouped into those who perceived their disease to be severe
(responding ‘quite severe’, ‘very severe’ or ‘extremely severe’)
and those who perceived their disease to be non-severe (re-
sponding ‘not particularly severe’ or ‘not severe at all’).
Results
Study population
Population demographics have been reported previously.2 There
were approximately equal proportions of males (48.9%) and
females (51.1%), and just over half of the respondents were in
the older age group (55.1% aged 45–74 vs 44.9% aged 18–44).
About three-quarters of the respondents (74.6%) were diagnosed
with PsO alone, and in the remaining quarter, respondents were
diagnosed with PsA alone (15.1%) or PsA with PsO (10.3%).
Most respondents (72.7%) with PsO alone considered their con-
dition to be non-severe; 26.9% considered their condition to be
severe.2 Fewer respondents reporting PsA with or without PsO
(PsA  PsO) considered their condition to be non-severe
(38.9%); 58.7% considered their condition to be severe. Overall,
10.7% of those reporting PsO alone had never seen a dermatolo-
gist and 14.3% of those reporting PsA  PsO had never seen a
rheumatologist.2
Treatment
Patterns of treatment use Diagnosis (PsO alone vs
PsA  PsO) did not affect the proportion of respondents who
used or had tried emollients and topical cortisones, which were
the most commonly used treatments for both groups (Fig. 1).
All other treatments (alternative therapies, light treatment, oral
or injectable methotrexate, other oral medications, injectable or
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Figure 1 Patterns of treatment use reported by respondents with (a) psoriasis (PsO) alone and (b) psoriatic arthritis (PsA) with or without
PsO. *Significant difference between diagnostic groups (a) and (b) (Bonferroni-corrected z-tests, total a = 0.05). UV, ultraviolet.
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intravenous biologics or ‘other treatment’) were significantly
more likely to have been used, or tried and discontinued, by
respondents with PsA  PsO (Fig. 1). Respondents who
described their symptoms as severe were significantly more likely
to have used all treatments and at least three times more likely to
have used, or tried, systemic treatments than those who
described their symptoms as non-severe (Fig. 2). Systemic
treatments of any kind were used, or tried, by 14.6% of respon-
dents with PsO alone and by 58.5% of respondents with
PsA  PsO.
Systemic treatments discussed with a physician Respondents
who described their symptoms as severe were more than three
times as likely to have discussed systemic treatments with their
physician and more than four times as likely to have used, or
intended to use, systemic treatments than those who described
their symptoms as non-severe (Fig. 3). However, over one-third
of respondents (35.2%) with severe symptoms had never dis-
cussed a systemic treatment with their physician.
Respondents with PsA  PsO were significantly and substan-
tially more likely to have discussed systemic treatments with
their physician and to have used, or intended to use, such
treatments than respondents with PsO alone (Fig. 4). Member-
ship of a patient organization had a similar effect; respondents
who were members were significantly and substantially more
likely to have discussed systemic treatments, and to have used or
intended to use them, than non-members (Fig. 5).
Use of biologics Respondents who reported having used bio-
logics (n = 173) included a significantly higher proportion of
those with PsA  PsO than with PsO alone (31.8% vs 8.1%,
P < 0.05). Respondents who considered their symptoms to be
severe had used biologics significantly more often than those
who considered their symptoms to be non-severe (26.8% vs
6.7%, P < 0.05). The use of biologics was significantly and
strongly linked to membership of a patient organization; 40.7%
of respondents who were organization members had used bio-
logics compared with 6.9% of respondents who were not
(P < 0.05). There was also a significant link with age group; bio-
logics had been used by 21.5% of respondents aged 18–44 years
and by 8.1% of respondents aged 45–74 years (P < 0.05). No
significant gender differences were observed.
Respondents who had used biologics were asked whether the
suggestion to use them originally came from themselves or their
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Figure 2 Patterns of treatment use reported by respondents who perceive their symptoms to be (a) non-severe and (b) severe.
*Significant difference between symptom severity groups (a) and (b) (Bonferroni-corrected z-tests, total a = 0.05). UV, ultraviolet.
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physician; 35.5% had initiated treatment with biologics at the
suggestion of their physician, 29.8% made the suggestion them-
selves, and in 23.2% of cases, the suggestion came from both
themselves and their physician. Respondents aged 45–74 years
were least likely to have suggested biologics themselves (14.4%)
and were most likely to have started treatment with biologics at
the suggestion of their physician (53.8%). Respondents aged
18–44 years were most likely to have suggested biologics them-
selves (36.9%, significantly more likely than those aged
45–74 years, P < 0.05) and less likely to have started treatment
based on their physician’s recommendation (27.0%, significantly
less likely than those aged 45–74 years, P < 0.05). There was no
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Figure 3 Systemic treatments that were discussed with a doctor by respondents who perceive their symptoms to be (a) non-severe and
(b) severe. *Significant difference between symptom severity groups (a) and (b) (Bonferroni-corrected z-tests, total a = 0.05).
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Figure 4 Systemic treatments that were discussed with a physician by respondents with (a) psoriasis (PsO) alone and (b) psoriatic arthri-
tis (PsA) with or without PsO. *Significant difference between diagnostic groups (a) and (b) (Bonferroni-corrected z-tests, total a = 0.05).
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significant association between the source of the suggestion to
use biologics and membership of a patient organization, severity,
gender or diagnosis.
Respondent perceptions of long-term health risks of treat-
ments When asked about the health risks of treatments,
approximately half of the respondents thought there was a least
‘some health risk’ for topical steroids, whereas only about one-
third noted at least ‘some health risk’ for systemic treatments
(Fig. 6). Although most respondents (79.9%) felt able to com-
ment on the safety of topical steroids, 58.3–61.9% responded
‘don’t know’ when asked about the safety of systemic treatments.
A significantly (P < 0.05) lower proportion of respondents aged
18–44 years (47.7–49.1%) responded ‘don’t know’ than those
aged 45–74 (66.7–72.9%). The most influential factor in the
respondents’ ability to comment on the safety of systemic treat-
ments was membership of a patient organization; less than one-
third (26.1–30.7%) of respondents who were members answered
‘don’t know’, significantly less than the approximately two-
thirds (66.8–70.4%) who were not members (P < 0.05).
Respondent satisfaction with systemic treatments
Methotrexate Respondents using methotrexate, either oral or
injectable, were satisfied (‘very satisfied’ or ‘quite satisfied’),
indifferent (‘neither satisfied or dissatisfied’) or dissatisfied
(‘very dissatisfied or ‘quite dissatisfied’) with the treatment in
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Figure 5 Systemic treatments that were discussed with a doctor by respondents, split by membership of a patient organization: (a)
members and (b) non-members. *Significant difference between membership groups (a) and (b) (Bonferroni-corrected z-tests, total
a = 0.05). †Membership of a patient organization was indicated by 21.0% of respondents; of these, 52.3% had PsO alone (representing
14.6% of all respondents with PsO alone) and 47.7% had PsA with or without PsO (representing 46.5% of all respondents with PsA alone
and 35.3% of those with both conditions).
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Figure 6 Respondent perceptions of long-term medication safety (n = 1221).
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approximately equal measure (Fig. 7a). There was no significant
difference in respondents’ satisfaction between those with
PsA  PsO and those with PsO alone. Respondents aged 45–
74 years were significantly (P < 0.05) less likely to be indifferent
(22.7% vs 35.9%) and more likely to be ‘very dissatisfied’
(22.0% vs 7.4%) or ‘very satisfied’ (15.5% vs 7.2%) than those
aged 18–44 years. Respondents who were members of patient
organizations were significantly (P < 0.05) less likely to be ‘very
dissatisfied’ (7.6% vs 20.3%) and more likely to be ‘quite satis-
fied’ (32.0% vs 19.3%) than non-members.
Overall, 30.5% of the respondents using methotrexate were
dissatisfied with the treatment. A majority of the very/quite dis-
satisfied respondents reported side-effects as a reason for their
dissatisfaction (Fig. 7b). Other frequently cited reasons for dis-
satisfaction were concerns about safety and lack of efficacy
(Fig. 7b).
Biologics Respondent satisfaction with biologics varied by
diagnosis – a significantly higher proportion of respondents with
PsA  PsO were ‘quite satisfied’ compared with those with PsO
alone (Fig. 8a). Other differences were not statistically signifi-
cant, but there was a trend towards greater satisfaction and lower
dissatisfaction among respondents with PsA  PsO versus those
with PsO alone (Fig. 8a). Overall, 22.9% of respondents were
dissatisfied with biologics. The most frequently reported reasons
for dissatisfaction with biologics were a lack of efficacy and the
side-effects (Fig. 8b).
Discussion
The finding that 35.2% of respondents with self-perceived sev-
ere symptoms had not discussed systemic treatment with their
physician suggests that there are still too many patients in
Scandinavia not receiving adequate treatment for PsO and/or
PsA. Current or prior use of systemic therapy was reported by
14% of respondents with PsO alone. Although low, this pro-
portion is comparable with the proportion that was reported
in the MAPP study (7–14%, depending on severity).20 As
expected, a greater proportion of respondents with PsA, who
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PsA ± PsO, n = 149
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60.2%
Don’t know/do not wish to answer
It’s too difficult to remember to take the medication
Other
I don’t/I didn’t get any effect at all
I currently have/I had problems with my liver
I am/I was concerned about the long-term safety
I don’t/I didn’t get enough effect
I have/I had to change my lifestyle too much
(e.g. limit the alcohol intake or follow a specific diet)
I’m not/I wasn’t able to keep up with my daily activities
(e.g. missed work; missed family/personal)
I experienced side-effects (e.g. nausea, vomiting, diarrhoea or fever)
Figure 7 (a) Respondent satisfaction with oral or injectable methotrexate (n = 247), split by diagnosis of psoriasis (PsO) alone versus
psoriatic arthritis (PsA) with or without PsO and (b) reasons for dissatisfaction (multiple answers were allowed).
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generally had more severe symptoms, reported using systemic
treatments of any kind (58.5%) and biologic treatments
(31.8%). These figures are higher than the MAPP study in
which only 19% of respondents with PsA reported receiving
conventional oral therapy alone and 14% reported receiving
biologic treatments. However, the MAPP study included an
unmatched, parallel survey of dermatologists and rheumatolo-
gists who reported the prescription of systemic treatment at
higher rates than indicated by surveyed patients: dermatolo-
gists prescribed conventional oral therapies for 11.4% of
patients with PsO and biologics for 11.4%; rheumatologists
prescribed conventional oral therapies for 40.6% of patients
with PsA and dermatologists prescribed for 22.5%; biologics
were prescribed by rheumatologists for 21.4% of patients
and by dermatologists for 19.6%.23 Differences between these
physician-reported levels of treatment in the MAPP
study and levels of treatment reported by patients in both
the MAPP study and the NORPAPP may reflect the high
proportion of patients who were not regularly followed by a
physician.
The differences between the NORPAPP and the MAPP study
in terms of the proportion of patients reporting receiving treat-
ment, may reflect regional differences or changes in clinical prac-
tice over time. The use of systemic therapy in Germany
increased following the introduction of the National Goals for
Healthcare in Psoriasis (2010–2015) and implementation of the
first European S3-Guidelines in 2012.12,24,25 In 2013/2014, an
estimated 59.5% of patients with PsO had received systemic
therapy at least once within the previous 5 years compared with
47.3% in 2007 and 32.9% in 2005.7,25 Since then, with the WHO
resolution on PsO and the publication of updated European S3-
Guidelines in 2015,12 it is possible that the treatment of PsO and
PsA is also beginning to improve in other countries.
A factor that may have had an impact on the prescription and
use of systematic treatments is patient preference. Respondents
who were members of patient organizations were more likely to
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11.1%
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13.6%
14.1%
18.6%
28.1%
28.9%
Don’t know/do not wish to answer
It’s too difficult to remember to take the medication
I have/I had to change my lifestyle too much
(e.g. limit the alcohol intake or follow a specific diet)
Other
I am/I was concerned about the long-term safety
I don’t like to self-inject
I don’t/I didn’t get enough effect
I get/I got injection-site reactions
I’m not/I wasn’t able to keep up with my daily activities
(e.g. missed work; missed family/personal time)
I experienced side-effects
(e.g. nausea, vomiting, diarrhoea or fever)
I don’t/I didn’t get any effect at all
Figure 8 (a) Respondent satisfaction with biologic medications (n = 173), split by diagnosis of psoriasis (PsO) alone versus psoriatic
arthritis (PsA) with or without PsO and (b) reasons for dissatisfaction (multiple answers were allowed). *Significant difference between
diagnostic groups (Bonferroni-corrected z-tests, total a = 0.05).
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discuss systemic therapy with their physician and to have sys-
temic treatment prescribed. It appears that well-informed
respondents received more adequate treatment, although the risk
of ‘over-treatment’ cannot be assessed. Compared with those
aged 18–44 years, respondents aged 45–74 years were less likely
to have suggested biologics to their physician and were less likely
to have them prescribed, which may be linked. This implies that
a lack of information on newer treatments may be an issue for
both patients and physicians. The supposition of underinformed
physicians is made more plausible by the fact that many respon-
dents saw general practitioners (GPs) rather than specialists. In
Norway, it is strongly recommended that treatment with
methotrexate or cyclosporine is initiated by a specialist and that
the prescription of biologics is regulated by hospital dermatology
committees. In Sweden, although there is no formal restriction
for GPs or other physicians to prescribe systemic medication, in
practice, only dermatologists prescribe these treatments.
Levels of dissatisfaction with systemic treatments appeared to
be quite high with 30.5% of respondents indicating dissatisfac-
tion with methotrexate, mostly citing side-effects as the reason.
These results are largely comparable with the MAPP study, in
which approximately half of the patients indicated that they
found systemic treatment with oral agents to be burdensome,
mostly because of fears about side-effects.20,26 For biologics,
22.9% of respondents indicated dissatisfaction, with a lack of
efficacy and the side-effects being the most frequently cited rea-
sons. There was a trend towards greater satisfaction among
respondents with PsA than among those with PsO alone, but
there are no obvious reasons for this difference.
Level of knowledge and expectations could have played a role
in the level of treatment satisfaction. Although respondents who
were members of patient organizations were more burdened by
their disease (unublished data), they had greater levels of satis-
faction with methotrexate treatment than non-members. We
hypothesize that well-informed patients are more aware of what
to expect from treatment. Respondents aged 45–74 years were
less satisfied than those aged 18–44 years, so it may be that older
respondents were less well-informed of the benefits and side-
effects of treatment. This assumption is supported by the older
age-group’s larger fraction of ‘don’t know’ answers to the ques-
tions regarding systemic medication safety.
The results of the NORPAPP should be interpreted within
the context of its limitations. As with all retrospective surveys,
the data rely on the accurate recall of facts and interpretation
of questions by respondents. A strength of the survey is that,
like the MAPP study, participants were not identified based
on membership of patient organizations but were more
broadly representative of the cross-section of individuals living
with PsO and PsA in Sweden, Denmark and Norway. Never-
theless, 21% of respondents were members of patient organi-
zations and this could reflect the level of engagement of
individuals in the YouGov panels, which are made up of
individuals who have specifically opted in to participate in
online studies. Given the differences observed between respon-
dents who are members of patient organizations and those
who are not, this factor should be considered when interpret-
ing the survey results. Although the survey was conducted in
three different countries, data were pooled to provide a large
patient group, which allowed for broader subgroup analyses.
The justification for this is that Sweden, Denmark and Nor-
way have a similar prevalence of PsO and PsA,3–5 and have
largely similar healthcare systems and access to treatment (in-
cluding biologics).27,28
In conclusion, the results of this survey from Scandinavia
strongly support the findings from studies carried out in
other European countries and in the United States that
patients with PsO and/or PsA are often dissatisfied with the
treatment they receive. We also confirmed that few patients,
even if they have a serious disease, receive systemic treatment.
It appears likely that substantial numbers of Scandinavians
who perceive their PsO and/or PsA to be severe are not
receiving optimal treatment, particularly those aged 45–
74 years. Over one-third of respondents who perceived their
symptoms to be severe had never discussed systemic treat-
ment with a physician. Future studies should assess whether
better communication and an increased awareness of available
treatment options, among both patients and treating physi-
cians, can help to improve access to appropriate treatments
in the Scandinavian population suffering from severe PsO
and/or PsA.
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Appendix: Full questionnaire
Note that only those questions relevant to each individual were
presented to them.
Question 1: Do you have any type of psoriasis or psoriatic arthri-
tis?
i) Yes, and I’m diagnosed by a physician
ii) Yes, but I’m not diagnosed by a physician
iii) No, I do not have any type of psoriasis
iv) Do not know/do not wish to answer
Question 2: Which type of psoriasis have you been diagnosed
with by a physician?
i) Psoriasis on the skin, on nails or the scalp
ii) Psoriatic arthritis
iii) Both psoriasis (on skin, nails or scalp) and psoriatic
arthritis
iv) Do not know/do not wish to answer
Question 3: How long after your first symptoms were you diag-
nosed by a physician?
Separate answers for ‘Psoriasis (on skin, nails or scalp)’ and ‘Psori-
atic arthritis’
i) Within one year
ii) One year after
iii) 2–4 years after
iv) 5–9 years after
v) 10–14 years after
vi) 15–19 years after
vii) 20–29 years after
viii) 30 years after or more
ix) Do not know/do not wish to answer
Question 4: If you think about the past 12 months, how would
you rate the severity of your . . . ?
Separate answers for ‘Psoriasis (on skin, nails or scalp)’ and ‘Psori-
atic arthritis’
i) Not severe at all
ii) Not particularly severe
iii) Quite severe
iv) Very severe
v) Extremely severe
vi) Do not know/do not wish to answer
Question 5: Please describe in which way your psoriasis (on skin,
nails or scalp) is quite, very or extremely severe
• Free text answer
Question 6: Please describe in which way your psoriatic arthritis
is quite, very or extremely severe
• Free text answer
Question 7: Which symptoms or troubles due to your psoriasis
(on skin, nails or scalp) have you experienced in the past
12 months?
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i) Bleeding
ii) Burning
iii) Depression or anxiety
iv) Fatigue
v) Flaking/scales
vi) Itching
vii) Pain
viii) Plaque
ix) Pustules (pus-filled blisters)
x) Redness
xi) Swollen fingers or toes (e.g. sausage digits, so called
dactylitis)
xii) Tender or swollen tendons (e.g. on the heal, so called
enthesitis)
xiii) Nail psoriasis
xiv) Other symptoms
xv) I have not experienced any symptoms in the past
12 months
xvi) Do not know/do not wish to answer
Question 8: Where on the body have you had symptoms of pso-
riasis (on skin, nails or scalp) in the past 12 months?
i) Ankles
ii) Arm pit
iii) Back/spine
iv) Chest
v) Elbow
vi) Fingers
vii) Genitals
viii) Heels
ix) Hips
x) In skin folds (inverse psoriasis)
xi) Knees
xii) Nails
xiii) Neck
xiv) Scalp
xv) Shoulders
xvi) The bend of the arm
xvii) Palm of hands or sole of feet
xviii) Toes
xix) Ears
xx) Wrist
xxi) Other body location
xxii) I have not experienced any symptoms in the past
12 months
xxiii) Do not know/do not wish to answer
Question 9: Based on the amount of psoriasis that could be cov-
ered by the palm of your hand, about how many palms would
you say that you currently have across your entire body?
i) None
ii) Less than 1 palm
iii) 1–3 palms
iv) 4–9 palms
v) 10–19 palms
vi) 20 palms or more
vii) Do not know/do not wish to answer
Question 10: How often have you had relapses or flare-ups of
your psoriasis (on the skin, nails or scalp) in the past three years?
With relapse or flare-up, we mean periods when symptoms have
worsened.
i) I’ve had constant symptoms, with no remission
ii) Every week
iii) Every month
iv) Every quarter
v) Every six months
vi) Every year
vii) Every two years
viii) Every three years (once in the past three years)
ix) I haven’t had any flare-up or relapses in the past three
years
x) Do not know/do not wish to answer
Question 11: Have you experienced pain or soreness in any of
your joints?
i) Yes
ii) Yes, I have it currently
iii) Yes, in the past 12 months
iv) Yes, more than one year ago
v) No, never
vi) Do not know/do not wish to answer
Question 12: In which location is/were your joint pain or sore-
ness most bothersome?
i) Ankles
ii) Back/spine
iii) Elbow
iv) Fingers/hands
v) Heel
vi) Sole of foot
vii) Hips
viii) Knees
ix) Neck
x) Shoulders
xi) Toes
xii) Wrist
xiii) Other body location
xiv) Do not know/do not wish to answer
Question 13: To what extent do you agree that you have experi-
enced the following in the past 12 months due to your psoriasis?
Each statement scored from 1 (do not agree at all) to 5 (totally agree)
i) I’ve felt embarrassed or self-conscious because of my skin
symptoms
ii) The topical treatment (such as ointments or creams) of my
skin has been taking up too much time
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iii) The topical treatment (such as ointments or creams) of my
skin has been inconvenient or messy
Question 14: To which extent do you agree that you have experi-
enced the following in the past 12 months due to your psoriasis/
psoriatic arthritis?
Each statement scored from 1 (do not agree at all) to 5 (totally agree)
My disease has . . .
i) . . . caused sleeping disorders/lack of sleep
ii) . . . prevented me from maintaining good hygiene (e.g.
showering or brushing the teeth)
iii) . . . interfered with my daily routines such as getting out
of bed, eating, cleaning, shopping or cooking
iv) . . . prevented me from wearing specific clothes/shoes
v) . . . prevented me from participating in a social activity
vi) . . . prevented me from doing sports or a leisure activity
vii) . . . made me feel depressed or anxious
viii) . . . prevented me from having an active sex life
ix) . . . created difficulties in the relationship with my part-
ner, family, close friends or relative
x) . . . created difficulties in the relationship with acquain-
tances such as new friends or colleagues
Question 15: Have you experienced any trouble doing different
activities in the past 12 months due to your psoriatic arthritis?
i) Yes, getting dressed, including tying shoelaces and doing
buttons
ii) Yes, getting in and out of bed
iii) Yes, lifting a full cup or glass to my mouth
iv) Yes, walking outdoors on flat ground
v) Yes, washing and drying my body
vi) Yes, bending down to pick up something up from the
floor
vii) Yes, turning faucets on and off
viii) Yes, getting in and out of a car
ix) Yes, having sex
x) Yes, other difficulties, what? – Free text answer
xi) No, I haven’t had any trouble
xii) Do not know/do not wish to answer
Question 16: Have you been absent from work or school in the
past 12 months due to your psoriasis/psoriatic arthritis?
i) Yes, I’ve been on a long-term sick leave
ii) Yes, a couple of days per week
iii) Yes, a couple of days per month
iv) Yes, a couple of days in the past year
v) Yes, only once in the past 12 months
vi) No
vii) I did not work or go to school in the past 12 months
viii) Do not know/do not wish to answer
Question 17: To what extent has your psoriasis/psoriatic arthritis
had a negative impact on your work/career or education since
you first developed symptoms?
i) No impact at all
ii) Quite low impact
iii) Impact
Question 18: Which types of healthcare professionals have you
seen in the past three years for your . . . ?
Separate answers for ‘Psoriasis (on skin, nails or scalp)’ and ‘Psori-
atic arthritis’
i) Allergist
ii) General practitioner
iii) Dermatologist
iv) Rheumatologist
v) Nurse
vi) Physiotherapist
vii) Orthopaedist
viii) Other healthcare professional
ix) I haven’t seen any healthcare professionals
x) Do not know/do not wish to answer
Question 19: What is the medical specialty of the healthcare pro-
fessional that you see most often for your . . . ?
Separate answers for ‘Psoriasis (on skin, nails or scalp)’ and ‘Psori-
atic arthritis’
i) Allergist
ii) General practitioner
iii) Dermatologist
iv) Rheumatologist
v) Nurse
vi) Physiotherapist
vii) Orthopaedist
viii) Other healthcare professional
ix) I Do not have a specific healthcare professional that I see
most often
x) Do not know/do not wish to answer
i) Do not know/do not wish to answer
Question 20: When did you last see a dermatologist for your
psoriasis (on skin, nails or scalp)?
i) In the past week
ii) In the past month
iii) In the past quarter
iv) In the past six months
v) In the past year
vi) In the past two years
vii) Three years ago or more
viii) I have never seen a dermatologist
ix) Do not know/do not wish to answer
Question 21: When did you last see a rheumatologist for your
psoriatic arthritis?
i) In the past week
ii) In the past month
iii) In the past quarter
iv) In the past six months
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v) In the past year
vi) In the past two years
vii) Three years ago or more
viii) I have never seen a rheumatologist
ix) Do not know/do not wish to answer
Question 22: If you think about the last time you were in
contact with a physician for your psoriasis (on skin, nails or
scalp), what. . .? were the main reasons that you were in
contact with the physician? You may choose several options
below.
i) Renewal of a prescription
ii) My symptoms had worsened
iii) General follow-up
iv) To talk about possible side-effects from medication
v) I had side-effects from a medication
vi) To discuss treatment options
vii) To discuss test results
viii) To take tests (such as a blood test)
ix) To receive light therapy
x) Psychological reasons (e.g. depression or anxiety)
xi) Other reason, what? – Free text answer
xii) Do not know/do not wish to answer
Question 23: If you think about the last time you were in contact
with a physician for your psoriatic arthritis, what. . .? were the
main reasons that you were in contact with the physician? You
may choose several options below.
i) Renewal of a prescription
ii) My symptoms had worsened
iii) General follow-up
iv) To talk about possible side-effects from medication
v) I had side-effects from a medication
vi) To discuss treatment options
vii) To discuss test results
viii) To take tests (such as a blood test)
ix) Psychological reasons (e.g. depression or anxiety)
x) Other reason, what? – Free text answer
xi) Do not know/do not wish to answer
Question 24: Overall, how satisfied or dissatisfied are you with
the healthcare system and treatment of your . . . ?
Separate answers for ‘Psoriasis (on skin, nails or scalp)’ and ‘Psori-
atic arthritis’
i) Very dissatisfied
ii) Neither dissatisfied nor satisfied
iii) Quite satisfied
iv) Very satisfied
v) Do not know/do not wish to answer
Question 25a: Why are you dissatisfied with the healthcare
system or treatment of your psoriasis (on skin, nails or
scalp)?
• Free text answer
Question 25b: Why are you satisfied with the healthcare’s system
or treatment of your psoriasis (on skin, nails or scalp)?
• Free text answer
Question 26a: Why are you dissatisfied with the healthcare’s sys-
tem or treatment of your psoriatic arthritis?
• Free text answer
Question 26b: Why are you satisfied with the heathcare’s system
or treatment of your psoriatic arthritis?
• Free text answer
Question 27: Have you ever changed physician because you were
dissatisfied with the management or treatment of your . . .?
Separate answers for ‘Psoriasis (on skin, nails or scalp)’ and ‘Psori-
atic arthritis’
i) Yes, once
ii) Yes, several times
iii) No, I never had the reason to change
iv) No, I never had the option to change
v) Do not know/do not wish to answer
Question 28: Have you had a dialogue with your physician about
using any of the below treatment options for your psoriasis/pso-
riatic arthritis?
Treatment options:
• Oral (tablet) or injectable methotrexate
• Oral (tablet) medications (other than methotrexate)
• Injectable or intravenous biologic medication
i) We discussed it but I never used it
ii) We discussed it and I used it/will use it
iii) We never discussed it
iv) Do not know/do not wish to answer
Question 29: Why did you decide not to use oral (tablet) or
injectable methotrexate?
• Free text answer
Question 30: Why did you decide not to use an oral (tablet)
medication (other than methotrexate)?
• Free text answer
Question 31: Why did you decide not to use an injectable or
intravenous biologic medication?
• Free text answer
Question 32: Are you using any of the following treatments for
your psoriasis/psoriatic arthritis?
Treatment options:
• Emollients (such as creams or ointments without cortisone)
• Topical cortisone treatments (topical steroids)
• Alternative treatments (e.g. from health food stores)
• Light treatment (e.g. UV treatment)
• Oral (tablet) or injectable methotrexate
• Oral (tablet) medications (other than methotrexate)
• Injectable or intravenous biologic medication
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• Other treatment
i) Yes, I’m currently using it
ii) No, I used it but stopped
iii) No, I never used it
iv) Do not know/do not wish to answer
Question 33: How long did you take the oral (tablet) or inject-
able methotrexate for before you stopped?
i) A week or less
ii) Two to three weeks
iii) A month
iv) A quarter (three months)
v) Half a year
vi) One year
vii) Two years
viii) More than two years
ix) Do not know/do not wish to answer
Question 34: In general, how satisfied or dissatisfied are/were
you with using oral (tablet) or injectable methotrexate?
i) Very dissatisfied
ii) Quite dissatisfied
iii) Neither dissatisfied nor satisfied
iv) Quite satisfied
v) Very satisfied
vi) Do not know/do not wish to answer
Question 35: Why are/were you dissatisfied with oral (tablet) or
injectable methotrexate?
i) I experienced side-effects, e.g. nausea, vomiting, diar-
rhoea or fever
ii) I currently have/had problems with my liver
iii) I have/had to change my lifestyle too much, e.g. limit the
alcohol intake or follow a specific diet
iv) I do not/did not get enough effect
v) I do not/did not get any effect at all
vi) I’m not/I wasn’t able to keep up with my daily activities
(e.g. missed work; missed family/personal time)
vii) I am/was concerned about the long-term safety
viii) It’s too difficult to remember to take the medication
ix) Other
x) Do not know/do not wish to answer
Question 36: For how long did you take the injectable or intra-
venous biologic medication before you stopped?
i) A week or less
ii) Two to three weeks
iii) A month
iv) A quarter (three months)
v) Half a year
vi) One year
vii) Two years
viii) More than two years
ix) Do not know/do not wish to answer
Question 37: When you first were prescribed the biologic medi-
cation, was it mainly yourself requesting the treatment or was it
the doctor’s suggestion?
i) The doctor first suggested that I use the treatment
ii) I was the one who first suggested that I use the treatment
iii) Both the doctor and I suggested that I use the treatment
iv) None of the above
v) Do not know/do not wish to answer
Question 38: How satisfied or dissatisfied are/were you with
using the biologic medication?
i) Very dissatisfied
ii) Quite dissatisfied
iii) Neither dissatisfied nor satisfied
iv) Quite satisfied
v) Very satisfied
vi) Do not know/do not wish to answer
Question 39: Why are/were you dissatisfied with the biologic
medication?
i) I experienced side-effects, e.g. nausea, vomiting, diar-
rhoea or fever
ii) I have/had to change my lifestyle too much, e.g. limit the
alcohol intake or follow a specific diet
iii) I do not/did not get enough effect
iv) I do not/did not get any effect at all
v) I’m not/I wasn’t able to keep up with my daily activities
(e.g. missed work; missed family/personal time)
vi) I do not like to self-inject
vii) I am/was concerned about the long-term safety
viii) It’s too difficult to remember to take the medication
ix) I get/got injection-site reactions
x) Other
xi) Do not know/do not wish to answer
Question 40: How would you evaluate the following treatment
types in regards to health risks of long-term use?
Treatment types
• Topical steroids, e.g. cortisone salves or creams
• Oral (tablet) or injectable methotrexate
• Oral (tablet) medications (other than methotrexate)
• Injectable or intravenous biologic medication
i) No health risks at all
ii) Quite low health risks
iii) Some health risks
iv) Quite large health risks
v) Very large health risks
vi) Do not know
Question 41: Do you think there is a good or bad range of treat-
ment options available today for your . . . ?
Separate answers for ‘Psoriasis (on skin, nails or scalp)’ and ‘Psori-
atic arthritis’
i) Very bad range
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ii) Quite bad range
iii) Neither good nor bad range
iv) Quite good range
v) Very good range
vi) Do not know
Question 42: If you think about your psoriasis/psoriatic arthritis
as a whole, what is most important to you in terms of support
or treatment?
• Free text answer
Question 43: Where do you get most of your information about
psoriasis/psoriatic arthritis? You may choose a maximum of
three options below.
i) Doctors
ii) Nurses
iii) Other health professionals
iv) Other patients
v) Family or friends
vi) Patient organisations
vii) Books
viii) Library
ix) Internet – search engines (such as Google)
x) Internet – specific disease-related sites
xi) Internet – forums
xii) Internet – other
xiii) Television
xiv) Radio
xv) Newspapers
xvi) Magazines
xvii) Other, what? – Free text answer
xviii) Do not know
Question 44: Are you a member of any patient organisation for
psoriasis or psoriatic arthritis?
Sweden
i) Yes, Psoriasisf€orbundet
ii) Yes, Reumatikerf€orbundet
iii) Yes, another organisation
iv) No
v) Do not know/do not wish to answer
Norway
i) Yes, Psoriasis- og eksemforbundet
ii) Yes, Norsk Revmatikerforbund
iii) Yes, another organisation
iv) No
v) Do not know/do not wish to answer
Denmark
i) Yes, Danmarks Psoriasis Forening
ii) Yes, Gigtforeningen
iii) Yes, another organisation
iv) No
v) Do not know/do not wish to answer
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